Abstract
Breakthrough Hemolysis in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Ravulizumab: Results of a 52-Week Extension from Two Phase 3 Studies
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have